Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02238990|
Recruitment Status : Recruiting
First Posted : September 12, 2014
Last Update Posted : May 3, 2018
The following trial is a multicenter and prospective research trial of the colposcopy unit of luebeck university and the national research center in Borstel, Germany.
The study is to identify and evaluate new biomarkers in human papilloma virus (HPV) associated malignancies and its preinvasive lesions of the cervix uteri. Fresh tissue samples being removed during conizations and/or hysterectomies are to be fixed in HOPE`s solution and analyzed according to their transcriptomes and methylosome. The hereby found candidates are to be validated using immunohistochemistry and RT [real-time] -PCR [polymerase chain reaction].
The project is meant to be followed by continuous studies developing a new test describing the malignant potential of HPV associated genital lesions.
|Condition or disease|
|Evaluation of New Tissue Biomarkers for Cervical Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Biomarkerscreening Via Transcriptome and Methylosome Analysis in Cervical Cancer and Its Preinvasive Lesions|
|Study Start Date :||September 2014|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
- CIN III (cervical intraepithelial neoplasia) lesions [ Time Frame: three years ]number of CIN III lesions
- cervical cancer [ Time Frame: three years ]number of cervical cancer probes
- HPV [ Time Frame: three years ]number and type of HPV infection of the analyzed probes
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02238990
|Contact: Daniel Beyer, PD Dr.||+49 451 500 firstname.lastname@example.org|
|Luebeck University, Department for obstetrics and gynecology||Recruiting|
|Luebeck, Schleswig Holstein, Germany, D-23538|
|Contact: Daniel Beyer, PD Dr. +49 451 500 2141 email@example.com|
|Contact: Torsten Goldmann, Prof. Dr. + 49 4537 188 230 firstname.lastname@example.org|
|Principal Investigator: Daniel Beyer, PD Dr.|
|Principal Investigator: Torsten Goldmann, Prof. Dr.|
|Principal Investigator:||Daniel Beyer, PD Dr.||University of Luebeck|
|Principal Investigator:||Torsten Goldmann, Prof. Dr.||Forschungszentrum Borstel|